GAD65 autoantibodies can be observed at high titres in patients with a clinical spectrum of neurological syndromes encompassing stiff-person syndrome, cerebellar ataxia, LE, and drug-resistant TLE. Here, GAD2 is linked to stiff-person syndrome.